A Phase 2 interventional study of Itepekimab SAR440340 in Chronic Obstructive Pulmonary Disease, sponsored by Sanofi. Completed at 23 sites in 7 countries. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.
Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2022, is one of 2 in phase 2, and was the 6th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 40+
Sanofi · Sites in France
Ages 18+
Sanofi · Sites in United States, Argentina, Austria and 19 more countries
Ages 40–85
Sanofi · Sites in United States, Argentina, Australia and 23 more countries
Ages 40–80
Sanofi · Sites in United States, Argentina, Belgium and 22 more countries
Ages 40–80
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2022.
This study's enrollment of 49 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 937 across the 12 interventional studies, 350 across the 3 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was an exploratory, two-part, 12-week, Phase 2a study evaluated the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years.
This study consisted of participants who had been on a standard-of-care (SoC) mono (long-acting β2-agonist [LABA]) or long-acting muscarinic antagonist [LAMA]), double (inhaled corticosteroid [ICS] + LABA, LABA + LAMA or ICS + LAMA), or triple (ICS + LABA + LAMA) controller therapy for COPD for at least 3 months prior to Screening (Visit 1) with stable dose and regimen for controller therapy for ≥1 month prior to Screening (Visit 1) and during the screening period. Participants would stay on their established controller medications for COPD throughout the duration of the study, with the exception of systemic corticosteroids and/or antibiotics used for acute exacerbation of COPD (AECOPD).
Part A would consist of participants who were former smokers with COPD; Part B would consist of participants who were current smokers with COPD.
The total study duration for each part (Part A and Part B) was approximately 36 weeks:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Smoking history of ≥10 pack-years
Documented or self-reported history of exacerbation having had ≥1 moderate or severe exacerbation within the 5 years prior to Screening (Visit 1), with at least 1 exacerbation treated with systemic :
A female participant was eligible to participate if she was not pregnant, not breastfed, and at least one of the following conditions applies:
Exclusion Criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm includes participants from 2 populations: Part A-former smokers and Part B-current smokers. Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 12 weeks
Drug: Itepekimab SAR440340
Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: subcutaneous
Also known as: REGN3500
Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Endobronchial Biopsies in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12
The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.
Time frame: Baseline (Week 0) and Week 12
Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Bronchial Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12
The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.
Time frame: Baseline (Week 0) and Week 12
Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Nasal Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12
The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.
Time frame: Baseline (Week 0) and Week 12
Change From Baseline in Interleukin-33 (IL-33) Treated Eosinophil-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12
The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). IL-33 treated eosinophil-associated gene signature is used to evaluate NES of endobronchial biopsies of former and current smokers, at baseline and Week 12. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.
Time frame: Baseline (Week 0) and Week 12
Change From Baseline in Interleukin-33 Treated Mast Cell-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12
The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). IL-33 treated mast cell-associated gene signature is used to evaluate NES of endobronchial biopsies of former and current smokers, at baseline and Week 12. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.
Time frame: Baseline (Week 0) and Week 12
Change From Baseline to Week 12 in Blood Eosinophil Count
Blood samples were collected at specified timepoints to assess change in blood eosinophil count. Baseline was defined as the last available value before first dose of study treatment.
Time frame: Baseline (Week 0) and Week 12
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Adverse Event of Special Interests (TEAESIs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Permanent Treatment Discontinuation
An AE was defined as any untoward medical occurrence in participant or clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. An AE of special interest (AESI) was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. SAEs were defined as any AE that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically important event. TEAEs were defined as AEs that developed, worsened or became serious during TE period (from first study treatment administration up to end of study).
Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Hematology During the Treatment-emergent Period
Blood samples were collected to determine the PCSA in hematology during the TE period (from the first treatment administration up to the end of study). Here, Hb = hemoglobin; g/L = grams per liter; M = male; F = female; v/v= volume by volume; LC = leukocyte count; NB = non-black; B = black; ULN = upper limit of normal and EO = eosinophils. Only parameters in which any participant had abnormality are reported.
Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Number of Participants With Potentially Clinically Significant Abnormalities in Clinical Chemistry During the Treatment-emergent Period
Blood samples were collected to determine the PCSA in chemistry during the TE period (first treatment administration up to the end of study). Here, mmol/L = millimoles/liter; LLN = lower limit of normal; mg/L = milligrams/liter and mcmol/L = micromoles/liter. Only parameters in which any participant had abnormality are reported.
Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Number of Participants With Potentially Clinically Significant Abnormalities in Urinalysis During the Treatment-emergent Period
Urine samples were collected to determine the PCSA in urine during the TE period (from the first treatment administration up to the end of study).
Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs During the Treatment-emergent Period
Participants were examined to determine the PCSA in vital signs during the TE period (from the first treatment administration up to the end of study). Here, SSBP = sitting systolic blood pressure; mmHg = millimeters of mercury; DFB = decrease from baseline and IFB = increase from baseline. Only parameters in which any participant had abnormality are reported.
Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) During the Treatment-emergent Period
Single 12-lead ECGs were obtained to determine PCSA during the TE period (from the first treatment administration up to the end of study). Here, QTcB= QT interval corrected by Bazett's formula and QTcF= QT interval corrected by Fridericia formula. Only parameters in which any participant had abnormality are reported.
Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Number of Participants With Treatment-emergent Antidrug Antibodies (ADA) to Itepekimab
Blood samples were collected to evaluate antibodies to itepekimab in serum. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing.
Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Serum Concentrations of Functional Itepekimab
Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.
Time frame: Pre-dose at Weeks 0, 4, 12 and 32
This study was conducted at 23 sites in 7 countries. A total of 102 participants were screened between 19 May 2022 and 07 November 2024 of which 53 were screen failures due to not meeting eligibility criteria. A total of 49 participants with chronic obstructive pulmonary disease (COPD) were enrolled in 2 groups (Part A: Former smokers and Part B: Current smokers) to receive itepekimab in this study.
| Milestone | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Started | 25 | 24 |
| Enrolled and treated | 23 | 24 |
| Completed | 23 | 24 |
| Not completed | 2 | 0 |
| Withdrew: Enrolled but not treated | 2 | 0 |
The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.
| score on a scale | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Endobronchial Biopsies in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12 | 0.691 (-2.17 to 1.84) | 0.526 (-0.74 to 2.53) |
The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.
| score on a scale | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Bronchial Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12 | 0.534 (-0.60 to 1.05) | 0.270 (-1.00 to 1.63) |
The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.
| score on a scale | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Nasal Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12 | -0.051 (-1.26 to 0.94) | 0.190 (-0.60 to 1.34) |
The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). IL-33 treated eosinophil-associated gene signature is used to evaluate NES of endobronchial biopsies of former and current smokers, at baseline and Week 12. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.
| score on a scale | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Change From Baseline in Interleukin-33 (IL-33) Treated Eosinophil-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12 | -0.095 (-1.28 to 1.43) | -0.006 (-2.29 to 0.34) |
The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). IL-33 treated mast cell-associated gene signature is used to evaluate NES of endobronchial biopsies of former and current smokers, at baseline and Week 12. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.
| score on a scale | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Change From Baseline in Interleukin-33 Treated Mast Cell-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12 | -0.327 (-1.44 to 2.28) | -0.044 (-2.10 to 1.00) |
Blood samples were collected at specified timepoints to assess change in blood eosinophil count. Baseline was defined as the last available value before first dose of study treatment.
| 10^9 cells/liter | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Change From Baseline to Week 12 in Blood Eosinophil Count | -0.06 ± 0.13 | -0.04 ± 0.11 |
An AE was defined as any untoward medical occurrence in participant or clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. An AE of special interest (AESI) was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. SAEs were defined as any AE that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically important event. TEAEs were defined as AEs that developed, worsened or became serious during TE period (from first study treatment administration up to end of study).
| Participants | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| TEAEs | 18 | 17 |
| TEAESIs | 1 | 0 |
| TESAEs | 1 | 2 |
| TEAEs leading to permanent study treatment discontinuation | 1 | 0 |
Blood samples were collected to determine the PCSA in hematology during the TE period (from the first treatment administration up to the end of study). Here, Hb = hemoglobin; g/L = grams per liter; M = male; F = female; v/v= volume by volume; LC = leukocyte count; NB = non-black; B = black; ULN = upper limit of normal and EO = eosinophils. Only parameters in which any participant had abnormality are reported.
| Participants | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Hb: >=185 g/ L (M); >=165 g/L (F) | 1 | 0 |
| Hematocrit: >=0.55 v/v (M); >=0.5 v/v (F) | 1 | 2 |
| LC: <3 x 10^9/ L (NB); <2 x 10^9/ L (B) | 1 | 0 |
| Neutrophils: <1.5 x 10^9/ L (NB); <1 x 10^9/ L (B) | 1 | 0 |
| Lymphocytes: >4 x 10^9/ L | 1 | 1 |
| Monocytes: >0.7 x 10^9/ L | 9 | 10 |
| Basophils: >0.1 x 10^9/ L | 4 | 3 |
| EO: >0.5x10^9/ L or >ULN (ULN >=0.5x10^9/ L) | 0 | 1 |
Blood samples were collected to determine the PCSA in chemistry during the TE period (first treatment administration up to the end of study). Here, mmol/L = millimoles/liter; LLN = lower limit of normal; mg/L = milligrams/liter and mcmol/L = micromoles/liter. Only parameters in which any participant had abnormality are reported.
| Participants | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Glucose: <=3.9 mmol/ L and <LLN | 2 | 0 |
| Glucose: >=11.1 mmol/L (unfasted); >=7 mmol/L (fasted) | 3 | 3 |
| Cholesterol: >=7.74 mmol/L | 0 | 2 |
| C-reactive protein: >2 ULN or >10 mg/ L | 5 | 4 |
| Potassium: >=5.5 mmol/L | 0 | 1 |
| Creatinine: >=30% change from baseline | 2 | 5 |
| Uric acid: >408 mcmol/L | 5 | 4 |
Urine samples were collected to determine the PCSA in urine during the TE period (from the first treatment administration up to the end of study).
| Participants | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Number of Participants With Potentially Clinically Significant Abnormalities in Urinalysis During the Treatment-emergent Period | 0 | 0 |
Participants were examined to determine the PCSA in vital signs during the TE period (from the first treatment administration up to the end of study). Here, SSBP = sitting systolic blood pressure; mmHg = millimeters of mercury; DFB = decrease from baseline and IFB = increase from baseline. Only parameters in which any participant had abnormality are reported.
| Participants | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| SSBP: <=95 mmHg and DFB>=20 mmHg | 0 | 1 |
| SSBP: >=160 mmHg and IFB>=20 mmHg | 1 | 1 |
| Weight: >=5% DFB | 6 | 0 |
| Weight: >=5% IFB | 5 | 1 |
Single 12-lead ECGs were obtained to determine PCSA during the TE period (from the first treatment administration up to the end of study). Here, QTcB= QT interval corrected by Bazett's formula and QTcF= QT interval corrected by Fridericia formula. Only parameters in which any participant had abnormality are reported.
| Participants | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Heart rate: >90 beats/minute | 2 | 1 |
| Heart rate: >90 beats/minute and IFB>=20 beats/minute | 2 | 0 |
| Heart rate: >100 beats/minute | 1 | 1 |
| Heart rate: >100 beats/minute and IFB>=20 beats/minute | 1 | 0 |
| PR interval, single beat: >200 milliseconds | 1 | 0 |
| QRS duration, single beat: >110 milliseconds | 2 | 2 |
| QRS duration, single beat: >120 milliseconds | 2 | 0 |
| QT interval, single beat: >500 milliseconds | 0 | 1 |
| QTcB interval, single beat: >450 milliseconds | 4 | 3 |
| QTcB interval, single beat: >480 milliseconds | 0 | 2 |
| QTcB interval, single beat: >500 milliseconds | 0 | 1 |
| QTcB interval, single beat - change from baseline: IFB >=30-60 milliseconds | 2 | 0 |
| QTcB interval, single beat - change from baseline: IFB >60 milliseconds | 0 | 1 |
| QTcF interval, single beat: >450 milliseconds | 2 | 3 |
| QTcF interval, single beat: >480 milliseconds | 0 | 1 |
| QTcF interval, single beat: >500 milliseconds | 0 | 1 |
| QTcF interval, single beat - change from baseline: IFB >60 milliseconds | 0 | 1 |
Blood samples were collected to evaluate antibodies to itepekimab in serum. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing.
| Participants | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Number of Participants With Treatment-emergent Antidrug Antibodies (ADA) to Itepekimab | 1 | 0 |
Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.
| nanograms per milliliter | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Week 0 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Week 4 | 36643.3 ± 30.93 | 36237.8 ± 32.91 |
| Week 12 | 59936.6 ± 28.69 | 61234.3 ± 39.83 |
| Week 32 | 1631.7 ± 60.38 | 1597.3 ± 75.38 |
Collected over SAEs and other AEs were collected from first dose of study treatment administration (Week 0) up to end of study, i.e., up to 32 weeks. All-cause mortality (Deaths) was collected from first dose of study treatment administration (Week 0) up to end of follow-up for death for each participant, i.e. up to approximately 38 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Former Smokers | 0/23 (0%) | 1/23 (4.3%) | 0/23 (0%) |
| Part B: Current Smokers | 0/24 (0%) | 2/24 (8.3%) | 0/24 (0%) |
| Event | Part A: Former Smokers | Part B: Current Smokers |
|---|---|---|
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 0/23 | 2/24 |
| DiverticulitisInfections and infestations | 1/23 | 0/24 |
| Urinary Tract Infection BacterialInfections and infestations | 1/23 | 0/24 |
The safety population included all enrolled participants who took at least 1 dose of study treatment.
| Age, Continuous(years) | Part A: Former Smokers | Part B: Current Smokers | Total |
|---|---|---|---|
| Mean | 63.8 ± 4.6 | 60.0 ± 6.7 | 61.9 ± 6.0 |
| Sex: Female, Male(Participants) | Part A: Former Smokers | Part B: Current Smokers | Total |
|---|---|---|---|
| Female | 10 | 9 | 19 |
| Male | 13 | 15 | 28 |
| Race (NIH/OMB)(Participants) | Part A: Former Smokers | Part B: Current Smokers | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 0 | 0 | 0 |
| White | 19 | 24 | 43 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Itepekimab Pharmacodynamic Normalized Enrichment Score (NES) in Endobronchial Biopsy(score on a scale) | Part A: Former Smokers | Part B: Current Smokers | Total |
|---|---|---|---|
| Median | 0.203 (0.00 to 2.38) | 0.357 (0.00 to 1.23) | 0.295 (0.00 to 2.38) |
| Itepekimab Pharmacodynamic Normalized Enrichment Score in Bronchial Brushings(score on a scale) | Part A: Former Smokers | Part B: Current Smokers | Total |
|---|---|---|---|
| Median | 0.719 (0.00 to 1.63) | 0.827 (0.26 to 2.38) | 0.813 (0.00 to 2.38) |
| Itepekimab Pharmacodynamic Normalized Enrichment Score in Nasal Brushings(score on a scale) | Part A: Former Smokers | Part B: Current Smokers | Total |
|---|---|---|---|
| Median | 1.620 (0.58 to 2.52) | 0.961 (0.27 to 2.24) | 1.175 (0.27 to 2.52) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from May 2022 to primary completion in Mar 2025, 33 months.
Results were first posted in Aug 2026, 1 year 5 months after primary completion. A results delay was requested in Mar 2026.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 33 months is above that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Itepekimab
Pulmonary Disease, Chronic Obstructive →